OXUR.BR

Oxurion NV [OXUR.BR] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

OXUR.BR Stock Summary

Does not have any significance market cap ($738.44K)

An RSI reading of 30 or below indicates an oversold or undervalued condition.

Top 10 Correlated ETFs

OXUR.BR

Top 10 Correlated Stocks

OXUR.BR

In the News

OXUR.BR Financial details

Company Rating

Market Cap

738.44K

Income

-55.61M

Revenue

1.57M

Book val./share

Cash/share

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

05 Apr 2024

P/E

Forward P/E

PEG

P/S

3.52

P/B

-0.01

P/C

P/FCF

-0.11

Quick Ratio

0.29

Current Ratio

0.58

Debt / Equity

LT Debt / Equity

EPS (TTM)

-0.73

EPS next Y

EPS next Q

EPS this Y

-51.32%

EPS next Y

EPS next 5Y

EPS last 5Y

-18.2%

Revenue last 5Y

-35.48%

Revenue Q/Q

-46.27%

EPS Q/Q

-62.05%

SMA20

-33.33%

SMA50

-63.64%

SMA100

-82.61%

Inst Own

Inst Trans

ROA

-264%

ROE

1120%

ROC

61.65%

Gross Margin

14%

Oper. Margin

-3688%

Profit Margin

-5327%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

1.0E-4-0.0104

52W High

52W Low

RSI

23.54

Rel Volume

0.01

Avg Volume

104.97M

Volume

596.55K

Perf Week

-16.27%

Perf Month

-50%

Perf Quarter

-86%

Perf Half Y

-87.43%

Beta

0.514

Volatility

0%, 0.01%

Prev Close

-2.78%

Price

0.035

Change

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 104.97M
Market Capitalization 738.44K
Employee 20
CEO Mr. Pascal Ghoson
Headquarters Leuven,BE
IPO Date 2006-07-07
Website https://www.oxurion.com

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.